BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33883447)

  • 21. Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.
    Klein C; Karanges E; Spiro A; Wong A; Spencer J; Huynh T; Gunasekaran N; Karl T; Long LE; Huang XF; Liu K; Arnold JC; McGregor IS
    Psychopharmacology (Berl); 2011 Nov; 218(2):443-57. PubMed ID: 21667074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute and chronic effects of cannabidiol on Δ⁹-tetrahydrocannabinol (Δ⁹-THC)-induced disruption in stop signal task performance.
    Jacobs DS; Kohut SJ; Jiang S; Nikas SP; Makriyannis A; Bergman J
    Exp Clin Psychopharmacol; 2016 Oct; 24(5):320-330. PubMed ID: 27690502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An assessment of concurrent cannabidiol and Δ⁹-tetrahydrocannabinol administration in place aversion and taste avoidance conditioning.
    Hempel BJ; Clasen MM; Nelson KH; Woloshchuk CJ; Riley AL
    Exp Clin Psychopharmacol; 2018 Apr; 26(2):205-213. PubMed ID: 29648861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of daily Δ
    Withey SL; Kangas BD; Charles S; Gumbert AB; Eisold JE; George SR; Bergman J; Madras BK
    Drug Alcohol Depend; 2021 Apr; 221():108629. PubMed ID: 33640678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review.
    Freeman AM; Petrilli K; Lees R; Hindocha C; Mokrysz C; Curran HV; Saunders R; Freeman TP
    Neurosci Biobehav Rev; 2019 Dec; 107():696-712. PubMed ID: 31580839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Δ9-THC and cannabidiol vapor inhalation in male and female rats.
    Javadi-Paydar M; Nguyen JD; Kerr TM; Grant Y; Vandewater SA; Cole M; Taffe MA
    Psychopharmacology (Berl); 2018 Sep; 235(9):2541-2557. PubMed ID: 29907926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of interaction between delta9-tetrahydrocannabinol (delta-THC) and cannabidiol (CBD) in aggression, muscle control and body temperature experiments in mice.
    Ham MT; De Jong Y
    Psychopharmacologia; 1975; 41(2):169-74. PubMed ID: 1171491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabidiol Exerts Anticonvulsant Effects Alone and in Combination with Δ
    Javadzadeh Y; Santos A; Aquilino MS; Mylvaganam S; Urban K; Carlen PL
    Cells; 2024 Mar; 13(6):. PubMed ID: 38534310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
    Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.
    Fusar-Poli P; Crippa JA; Bhattacharyya S; Borgwardt SJ; Allen P; Martin-Santos R; Seal M; Surguladze SA; O'Carrol C; Atakan Z; Zuardi AW; McGuire PK
    Arch Gen Psychiatry; 2009 Jan; 66(1):95-105. PubMed ID: 19124693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol.
    Bergeria CL; Strickland JC; Spindle TR; Kalaba M; Satyavolu PU; Feldner M; Vandrey R; Bonn-Miller M; Peters EN; Weerts E
    Exp Clin Psychopharmacol; 2023 Apr; 31(2):312-317. PubMed ID: 35467921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of delta 9-tetrahydrocannabinol alone and in combination with cannabidiol on fixed-interval performance in rhesus monkeys.
    Brady KT; Balster RL
    Psychopharmacology (Berl); 1980; 72(1):21-6. PubMed ID: 6258188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
    Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
    JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats.
    Malone DT; Jongejan D; Taylor DA
    Pharmacol Biochem Behav; 2009 Aug; 93(2):91-6. PubMed ID: 19393686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Critical Review of the Role of the Cannabinoid Compounds Δ
    Jones É; Vlachou S
    Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Δ(9) -tetrahydrocannabinol in Sprague-Dawley rats.
    Taffe MA; Creehan KM; Vandewater SA
    Br J Pharmacol; 2015 Apr; 172(7):1783-91. PubMed ID: 25425111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interactions between cannabidiol and Δ
    Todd SM; Zhou C; Clarke DJ; Chohan TW; Bahceci D; Arnold JC
    Eur Neuropsychopharmacol; 2017 Feb; 27(2):132-145. PubMed ID: 28043732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis.
    Jamontt JM; Molleman A; Pertwee RG; Parsons ME
    Br J Pharmacol; 2010 Jun; 160(3):712-23. PubMed ID: 20590574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
    Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
    Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model.
    Mitchell VA; Harley J; Casey SL; Vaughan AC; Winters BL; Vaughan CW
    Neuropharmacology; 2021 May; 189():108529. PubMed ID: 33741405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.